Lightbed Study 2 – Now Open
Please email research@niim.com.au to register your interest.
Monitoring treatment effect of photo-dynamic therapy using a lightbed (Light-bed-PDT) in cancer patients by Circulating Tumour Cell (CTC) analysis
Background
Prevalence of cancer diagnosis is high and attributable to 30% of all deaths in Australia. There is a need for better treatment combined with reliable assessments of treatment effectiveness. This pilot intervention study aims to assess the treatment effectiveness and safety of Light-bed-PDT for patients with cancer using Circulating Tumour Cell (CTC) specimen analyses.
What is Photodynamic Therapy (PDT)
PDT consists of two steps, the oral administration of a chlorophyll-based algal-derived food-grade liquid photosensitiser (Step 1), followed by LED light therapy the next day (Step 2). The photosensitiser has been shown to concentrate in cancer cells, and is activated by light from Light Emitting Diodes (LED) inducing cancer cell death, while also stimulating the immune system.
SEEKING ADULTS DIAGNOSED WITH ANY TYPE OF CANCER
Who can participate in this study?
• Adults diagnosed with cancer
• CTC count between 5-20 CTC/ml
• Not on chemotherapy or radiotherapy
• Not planning to start any new treatments within the next 14 days
• Not suffering from porphyria
• Not suffering from claustrophobia, or anxiety, if in confined space
• Able to provide informed consent
What will I be asked to do?
1. To check your eligibility, you will need a doctor’s referral for a CTC test and assessment for HBOT.
2. If eligible, there will be 5 visits to NIIM over a period of 3 months.
3. Day 1 pm will involve enrolment and consent, a Quality-of-Life questionnaire, and sublingual (under the tongue)
administration of the photosensitiser
4. Day 2 am you receive the treatment of HBOT + LBT (90 min + 30 min).
5. Visit 3, one week after treatment, you will be asked to do the follow-up CTC blood test, and a tolerability
questionnaire (15 min).
6. Please make an appointment with your referring doctor to discuss your CTC results.
7. Follow-up tests at 3-months include the CTC and tumour marker blood tests and QoL questionnaire.
Please note:
1) Participation is voluntary.
2) There are costs associated with participating in this trial.
3) All clinical trials have been approved by the NHMRC endorsed ethics committee. This includes any out-of-pocket-costs required for the trial to be conducted.
For more information:
Email: research@niim.com.au Subject heading: lightbed
